NEW YORK (GenomeWeb) – Roka Bioscience said in its Form 10-Q this week that it exercised an option to reduce the royalty rate it pays to Hologic. As a result, Roka paid $8 million and issued 865,063 shares of its common stock to Hologic subsequent to the closing of Roka's initial public offering last month. The option was exercisable if Roka raised less than $55 million in net proceeds from the IPO. Net proceeds from the offering were about $53.4 million, Roka said in its SEC document.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.